Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Phase 2 Study of Ladiratuzumab Vedotin for Unresectable Locally Advanced or Metastatic Solid Tumors
2019-001946-17Phase 2Unknown
- Sponsor
- Seagen Inc.
- Start
- Nov 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ladiratuzumab vedotin in Nonhematologic neoplasms, sponsored by Seagen Inc. Primary endpoint: Investigator-determined confirmed objective response rate (ORR) by RECIST v1.1. Status: unknown.
02
Drugs
ladiratuzumab vedotin
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2019-001946-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001946-17.